Orphazyme recruits new CEO

Just over two months after Orphazyme bid former CEO Kim Stratton farewell, the firm has found her replacement at US biotech firm Amgen.

Photo: Orphazyme/PR

Going forward, former Senior Vice President, General Manager of Amgen's US oncology business Christophe Bourdon will take the steering wheel at Orphazyme.

On April 1 he takes on the role of CEO at the Danish biotech company, thereby replacing Kim Stratton, who handed in her letter of resignation in December last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs